Rudolph Markus G, Shen Lucy Q, Lamontagne Stephen A, Luz John G, Delaney Joseph R, Ge Qing, Cho Bryan K, Palliser Deborah, McKinley Carol A, Chen Jianzhu, Wilson Ian A, Eisen Herman N
Center for Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
J Immunol. 2004 Mar 1;172(5):2994-3002. doi: 10.4049/jimmunol.172.5.2994.
We identify and consider some characteristics of a peptide antagonist for the Ag-specific receptor on 2C cells (the 2C TCR). The peptide, GNYSFYAL (called GNY), binds to H-2K(b), and a very high-resolution crystal structure of the GNY-K(b) complex at 1.35 A is described. Although the GNY peptide does not bind to L(d), the potency of GNY-K(b) as an antagonist is evident from its ability to specifically inhibit 2C TCR-mediated reactions to an allogenic agonist complex (QLSPFPFDL-L(d)), as well as to a syngeneic agonist complex (SIYRYYGL-K(b)). The crystal structure and the activities of alanine-substituted peptide variants point to the properties of the peptide P4 side chain and the conformation of the Tyr-P6 side chain as the structural determinants of GNYSFYAL antagonist activity.
我们鉴定并研究了一种针对2C细胞上Ag特异性受体(2C TCR)的肽拮抗剂的一些特性。该肽GNYSFYAL(称为GNY)与H-2K(b)结合,并描述了GNY-K(b)复合物在1.35 Å分辨率下的非常高分辨率的晶体结构。尽管GNY肽不与L(d)结合,但GNY-K(b)作为拮抗剂的效力可从其特异性抑制2C TCR介导的对同种异体激动剂复合物(QLSPFPFDL-L(d))以及同基因激动剂复合物(SIYRYYGL-K(b))反应的能力中明显看出。丙氨酸取代的肽变体的晶体结构和活性表明,肽P4侧链的性质和Tyr-P6侧链的构象是GNYSFYAL拮抗剂活性的结构决定因素。